Resources

References

Abramovits W, Fleischer AB, Jr., Jaracz E, et al. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream. J Drugs Dermatol 2008; 7: 1153–8.
Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118: 152-69.
Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808–16.
Astellas P. Protopic - Summary of Product Characteristics, 2009. http:/anti-infectives/Paris-Event/Live-Webcast.cfmemc.medicines.org.uk/medicine/8816/SPC/Protopic+0.1%25+ointment/
Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 2006; 144: 1-9.
Barbeau M, Bpharm HL. Burden of Atopic dermatitis in Canada. Int J Dermatol 2006; 45: 31-6.
Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006; 155: 145-51.
Bisgaard H, Simpson A, Palmer CN, et al. Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med 2008; 5: e131.
Bowcock AM, Cookson WO. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004; 13 Spec No 1: R43-55.
Chamlin SL, Frieden IJ, Williams ML, et al. Effects of atopic dermatitis on young American children and their families. Pediatrics 2004; 114: 607-11.
Chamlin SL, Mattson CL, Frieden IJ, et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med 2005; 159: 745-50.
Charman CR, Venn AJ, Williams H. Measuring atopic eczema severity visually: which variables are most important to patients? Arch Dermatol 2005; 141: 1146-51; discussion 1151.
Charman CR, Venn AJ, Williams HC. Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity score. Br J Dermatol 2002; 146: 1057-60.
Choi SJ, Song MG, Sung WT, et al. Comparison of transepidermal water loss, capacitance and pH values in the skin between intrinsic and extrinsic atopic dermatitis patients. J Korean Med Sci 2003; 18: 93-6.
Coghi S, Bortoletto MC, Sampaio SA, et al. Quality of life is severely compromised in adult patients with atopic dermatitis in Brazil, especially due to mental components. Clinics 2007; 62: 235-42.
Conde-Taboada A, Gonzalez-Barcala FJ, Toribio J. [Review and update of current understanding of childhood atopic dermatitis.]. Actas Dermosifiliogr 2008; 99: 690-700.
Correale CE, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999; 60: 1191-8, 1209-10.
Data on file: 4268/Sept08, 2008. Astellas Pharma Europe Ltd.
Di Nardo A, Wertz P, Giannetti A, et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998; 78: 27-30.
Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy 2004; 59 Suppl 78: 86–92.
Ekelund E, Saaf A, Tengvall-Linder M, et al. Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis. Am J Hum Genet 2006; 78: 1060-5.
Fivenson D, Arnold RJ, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8: 333-42.
FK506 Study Group. Phase III comparative study of FK506 ointment. Group comparison with betamethasone valerate in atopic dermatitis. Nishinihon J Dermatol 1997; 59: 870–879.
German Dermatological Society – Topical Dermatotherapy with Glucocorticoids – Therapeutic Index. Available from: http:/anti-infectives/Paris-Event/Live-Webcast.cfmwww.uniduesseldorf.de/AWMF/ll/013-034.htm [Accessed November 2009].
Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007; 214: 61–7.
Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28–38.
Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53: S186–94.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 92, Suppl: 44-47.
Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-8.
Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695–9.
Herd RM, Tidman MJ, Prescott RJ, et al. The cost of atopic eczema. Br J Dermatol 1996; 135: 20-3.
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1–191.
Hoffjan S, Nicolae D, Ostrovnaya I, et al. Gene-environment interaction effects on the development of immune responses in the 1st year of life. Am J Hum Genet 2005; 76: 696-704.
Hofman T, Cranswick N, Kuna P, et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006; 91: 905–10.
Holm EA, Wulf HC, Thomassen L, et al. Assessment of atopic eczema: clinical scoring and noninvasive measurements. Br J Dermatol 2007; 157: 674-80.
Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 1991; 96: 523-6.
Jensen JM, Folster-Holst R, Baranowsky A, et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004; 122: 1423-31.
Joint Formulary Committee. British National Formulary Vol. 58. London, 2009.
Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58–64.
Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35: 229-31.
Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151-8.
Koo JY, Fleischer AB, Jr., Abramovits W, et al. Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005; 53: S195–205.
Korstanje C, Dijkman J. Hydrocortisone 17-butyrate. In: Maibach H, Surber C, eds. Topical corticosteroids. Basel: Karger, 1992:435–50.
Krueger GG, Eichenfield L, Goodman JJ, et al. Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. J Drugs Dermatol 2007; 6: 185–93.
Langan SM, Thomas KS, Williams HC. What is meant by a "flare" in atopic dermatitis? A systematic review and proposal. Arch Dermatol 2006; 142: 1190-6.
Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. MedGenMed 2006; 8: 8.
Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med J 2006; 47: 293-306.
Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-7.
Maintz L, Novak N. Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol 2007; 17: 267-83.
Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289–95.
Martinez FD. The coming-of-age of the hygiene hypothesis. Respir Res 2001; 2: 129-32.
Mihm MC, Jr., Soter NA, Dvorak HF, et al. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol 1976; 67: 305-12.
Mozaffari H, Pourpak Z, Pourseyed S, et al. Quality of life in atopic dermatitis patients. J Microbiol Immunol Infect 2007; 40: 260-4.
Naylor M, Elmets C, Jaracz E, et al. Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J Dermatolog Treat 2005; 16: 149–53.
Novak N, Kwiek B, Bieber T. The mode of topical immunomodulators in the immunological network of atopic dermatitis. Clin Exp Dermatol 2005; 30: 160-4.
Oranje AP, Glazenburg EJ, Wolkerstorfer A, et al. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007; 157: 645-8.
Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47–57.
Paller AS, Lebwohl M, Fleischer AB, Jr., et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810–22.
Pastore S, Mascia F, Girolomoni G. The contribution of keratinocytes to the pathogenesis of atopic dermatitis. Eur J Dermatol 2006; 16: 125-31.
Proksch E, Folster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006; 43: 159-69.
PROTOPIC – Summary of Product Characteristics. Available from: http:/anti-infectives/Paris-Event/Live-Webcast.cfmwww.emea.europa.eu/humandocs/PDFs/EPAR/protopic/emea-combined-h374en.pdf [Accessed November 2009].
Reitamo S, Allsopp R. Treatment with twice-weekly tacrolimus ointment in patients with moderate-to-severe atopic dermatitis: Results from two randomized, multicentre, comparative studies J Dermatolog Treat 2009; In press.
Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554–62.
Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282–9.
Reitamo S, Remitz A, Haahtela T. Hit early and hit hard in atopic dermatitis and not only in asthma. Allergy 2009; 64: 503-4.
Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547–55.
Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539–46.
Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136: 999–1006.
Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol 2007; 87: 54–61.
Remitz A, Reitamo S. Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf 2009; 8: 501–6.
Roelofzen JH, Aben KK, Khawar AJ, et al. Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders. Eur J Dermatol 2007; 17: 416–21.
Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004; 112: 352-63.
Rubins A, Gutmane R, Valdmane N, et al. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol 2005; 125: 68–71.
Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157: 861–73.
Sandilands A, O'Regan GM, Liao H, et al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol 2006; 126: 1770-5.
Schittek B, Paulmann M, Senyurek I, et al. The role of antimicrobial peptides in human skin and in skin infectious diseases. Infect Disord Drug Targets 2008; 8: 135-43.
Schmitt J, Langan S, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007; 120: 1389-98.
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993; 186: 23-31.
Sole D, Camelo-Nunes IC, Wandalsen GF, et al. Prevalence of symptoms of asthma, rhinitis, and atopic eczema in Brazilian adolescents related to exposure to gaseous air pollutants and socioeconomic status. J Investig Allergol Clin Immunol 2007; 17: 6-13.
Soter NA, Fleischer AB, Jr., Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44: S39–46.
Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin Dermatol 2008; 9: 233–44.
Stewart AW, Mitchell EA, Pearce N, et al. The relationship of per capita gross national product to the prevalence of symptoms of asthma and other atopic diseases in children (ISAAC). Int J Epidemiol 2001; 30: 173-9.
Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax 2000; 55 Suppl 1: S2-10.
Strachan DP. Hay fever, hygiene, and household size. BMJ 1989; 299: 1259-60.
Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348–56.
Torres-Borrego J, Molina-Teran AB, Montes-Mendoza C. Prevalence and associated factors of allergic rhinitis and atopic dermatitis in children. Allergol Immunopathol (Madr) 2008; 36: 90-100.
Weinmann S, Kamtsiuris P, Henke KD, et al. The costs of atopy and asthma in children: assessment of direct costs and their determinants in a birth cohort. Pediatr Allergy Immunol 2003; 14: 18-26.
Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103: 125-38.
Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131: 383-96.
Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131: 406-16.
Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314-24.
Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742–50.
Wollenberg A, Sidhu MK, Odeyemi I, et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2008; 159: 1322–30.
Wollenberg A, Wen S, Bieber T. Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry 1999; 37: 147-55.
Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351: 1225-32.
Zeyrek CD, Zeyrek F, Sevinc E, et al. Prevalence of asthma and allergic diseases in Sanliurfa, Turkey, and the relation to environmental and socioeconomic factors: is the hygiene hypothesis enough? J Investig Allergol Clin Immunol 2006; 16: 290-5.

Disclaimer:
The Atopic Dermatitis Knowledge centre contained within www.epgonline.org and available at www.atopicdermatitisinfo.org is intended to be for educational use only and not designed to provide medical advice or professional services.

Atopic Dermatitis Knowledge Centre

Resources

References